Page 111 - 《中国药房》2026年9期

[ 6 ] BRACKMAN D，ECKERT D，MENON R，et al. Veneto‐ analytical method for venetoclax in mouse plasma，and its
clax exposure-efficacy and exposure-safety relationships application to pharmacokinetic studies[J]. J Chromatogr B，
in patients with treatment-naïve acute myeloid leukemia 2020，1152：122176.
who are ineligible for intensive chemotherapy[J]. Hematol [16] DÖHNER H，WEI A H，APPELBAUM F R，et al. Diagnosis
Oncol，2022，40（2）：269-279. and management of AML in adults：2022 recommenda‐
[ 7 ] FREISE K J，SHEBLEY M，SALEM A H. Quantitative tions from an international expert panel on behalf of the
prediction of the effect of CYP3A inhibitors and inducers ELN[J]. Blood，2022，140（12）：1345-1377.
on venetoclax pharmacokinetics using a physiologically [17] 中华医学会血液学分会白血病淋巴瘤学组. 成人急性髓
based pharmacokinetic model[J]. J Clin Pharmacol，2017， 系白血病（非急性早幼粒细胞白血病）中国诊疗指南：
57（6）：796-804. 2017年版[J]. 中华血液学杂志，2017，38（3）：177-182.
[ 8 ] LIU H，MICHMERHUIZEN M J，LAO Y B，et al. [18] JONES A K，FREISE K J，AGARWAL S K，et al. Clinical
Metabolism and disposition of a novel B-cell lymphoma-2 predictors of venetoclax pharmacokinetics in chronic
inhibitor venetoclax in humans and characterization of its lymphocytic leukemia and non-Hodgkin’s lymphoma
unusual metabolites[J]. Drug Metab Dispos，2017，45（3）： patients：a pooled population pharmacokinetic analysis[J].
294-305. AAPS J，2016，18（5）：1192-1202.
[ 9 ] YANG Y L，QIAN Z Y，ZHAO Y，et al. LC-MS/MS [19] 王昀琪，王慧芳，付强，等. 维奈克拉联合阿扎胞苷治疗
methods for determination of venetoclax in human plasma 急性髓系白血病患者中维奈克拉血药浓度监测及与疗
and cerebrospinal fluid[J]. Biomed Chromatogr，2023，37 效关系[J]. 临床血液学杂志，2024，37（9）：643-648，656.
（12）：e5738. [20] KOBAYASHI M，YASU T，SUZAKI K，et al. Utility of
[10] YASU T，GANDO Y，NOMURA Y，et al. Determination therapeutic drug monitoring of venetoclax in acute
of venetoclax concentration in plasma using high- myeloid leukemia[J]. Med Oncol，2022，39（12）：259.
performance liquid chromatography[J]. J Chromatogr Sci， [21] IZUTSU K，YAMAMOTO K，KATO K，et al. Phase 1/2
2023，61（5）：480-483. study of venetoclax，a Bcl-2 inhibitor，in Japanese patients
[11] GONG J Q X，SULEIMAN A A，MENON R，et al. Pooled with relapsed or refractory chronic lymphocytic leukemia
population pharmacokinetic analyses of venetoclax in pa‐ and small lymphocytic lymphoma[J]. Int J Hematol，2021，
tients across indications and healthy subjects from phase 113（3）：370-380.
1，2，and 3 clinical trials[J]. J Clin Pharmacol，2023，63 [22] 孙文利，杨芮庚，刘瑞，等. 维奈克拉血药浓度监测在急
（8）：950-960. 性髓系白血病中的临床应用[J]. 实用药物与临床，2025，
[12] YANG X，MEI C，HE X Y，et al. Quantification of veneto‐ 28（5）：344-349.
clax for therapeutic drug monitoring in Chinese acute [23] AGARWAL S，GOPALAKRISHNAN S，MENSING S，
myeloid leukemia patients by a validated UPLC-MS/MS et al. Optimizing venetoclax dose in combination with low
method[J]. Molecules，2022，27（5）：1607. intensive therapies in elderly patients with newly diag‐
[13] PHILIPPE M，GUITTON J，GOUTELLE S，et al. Pharma‐ nosed acute myeloid leukemia：an exposure-response
cokinetic consideration of venetoclax in acute myeloid analysis[J]. Hematol Oncol，2019，37（4）：464-473.
leukemia patients：a potential candidate for TDM a short [24] YANG Y F，ZHAO L，WU Y. The venetoclax conundrum：
communication[J]. Ther Drug Monit，2024，46（1）：127-131. therapeutic drug monitoring of venetoclax：correlation
[14] 金洁，周一乐. WHO 2022第5版急性髓系白血病分类解 with response in acute myeloid leukemia[J]. Blood，2025，
读[J]. 临床血液学杂志，2023，36（3）：145-147. 146：5234.
[15] EISENMANN E D，JIN Y，WEBER R H，et al. Develop‐ （收稿日期：2026-01-14 修回日期：2026-04-17）
ment and validation of a sensitive UHPLC-MS/MS （编辑：舒安琴）

中国药房 2026年第37卷第9期 China Pharmacy 2026 Vol. 37 No. 9 · 1205 ·